acute pancreatitis and semaglutide Small risk of severe with weight-loss jabs, UK regulator warns | Weight-loss drugs Reconciling GLP-1s and Pancreatitis

A Trustpilot review from early 2026 describes Southend stopping medication shipments to patients in approximately 20 states during a transition to a new, larger production facility, with customer service becoming unreachable and estimated timelines for resolution passing without fulfillment

This combination approach has become a standard-of-care strategy in diabetes management guidelines

Clinical trials show semaglutide produces 1015% weight loss over 68 weeks in patients with obesity, with effects appearing within 46 weeks of consistent dosing

Changes to facial fat, skin elasticity, and texture are common complaints among patients taking GLP-1 medications

Most patients regain weight after stopping GLP-1 medications, with clinical trials showing approximately two-thirds of lost weight returns within one year

Diabetes and obesity, while primary cardiometabolic diseases, have significant negative effects on muscles, tendons and joints